A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer
The Oncologist, 07/20/2012Hurwitz H et al.
Based on the results, the first–line treatment of U.S. patients with metastatic colorectal cancer (mCRC) using a biweekly combination of Capecitabine administered for 7days biweekly with oxaliplatin (XELOX) and bevacizumab at the doses studied cannot be recommended. XELOX triweekly cycle (Q3W) remains the preferred schedule for the management of mCRC.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.